KeifeRx is currently investigating or plans to investigate its TKI formulations in neurodegenerative diseases, including Alzheimer’s disease (AD) and Mild Cognitive Impairment (MCI), and movement disorders, including Lewy Body Dementia (LBD) and Amyotrophic Lateral Sclerosis (ALS) and Huntington’s disease. Additionally, KeifeRx is advancing novel TKIs targeting inflammatory diseases, including mast cell activated syndromes (MCAS), Lyme disease, and Urticaria, as well as neuro-inflammatory conditions that are features of neurodegeneration.
KeifeRx’s clinical pipeline is led by KFRX01 (Nilotinib BE), an optimized re-formulation with improved bioavailability and solubility than nilotinib (Tasgina®). KFRX01 is being developed for the treatment of early Alzheimer’s disease.